Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Safety and Tolerability of SB-681323 Administered Via the Intravenous Route

NCT00439881 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00439881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00439881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Safety and Tolerability of SB-681323 Administered Via the Intravenous Route
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2006
Completion date
Not reported
Enrollment
16
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid, inflammation